NCT00075647
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer treatment 2 completed NCT00063947
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer treatment 1 completed NCT01233505
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors treatment 1 terminated NCT04902261
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer treatment 2 recruiting NCT00085371
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas treatment 2 completed NCT00047307
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer treatment 1 completed NCT01537107
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery treatment 1 completed NCT01145456
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT01806675
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy diagnostic 1 / 2 completed NCT00735917
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer treatment 2 completed NCT00028834
Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer treatment 2 completed NCT00028496
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer treatment 1 completed NCT01064622
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer treatment 1 / 2 completed NCT00482625
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery treatment 2 terminated NCT00091026
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer treatment 2 completed NCT00095966
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer treatment 2 completed NCT01846520
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers No drug interventions supportive_care Not Available completed NCT00383760
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients treatment 2 completed NCT00031694
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer treatment 2 completed NCT01232829
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer treatment 2 completed NCT01473940
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery treatment 1 completed NCT00031681
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) treatment 1 completed NCT01839981
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer treatment 1 completed NCT02166255
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery No drug interventions treatment 1 completed NCT02048943
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer treatment 1 withdrawn NCT00039403
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer treatment 1 completed NCT01191684
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer treatment 1 completed NCT00397384
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer treatment 1 completed NCT00397787
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine treatment 2 completed NCT00462553
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors treatment 1 completed NCT00030498
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction treatment 1 completed NCT01741597
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung diagnostic 1 withdrawn NCT01927393
Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer No drug interventions supportive_care Not Available withdrawn NCT00019006
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer No drug interventions treatment 1 completed NCT01227018
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer treatment 2 terminated NCT01835041
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer treatment 1 completed NCT01234935
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery treatment 2 completed NCT01666730
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer treatment 2 completed NCT00101348
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer treatment 1 / 2 completed NCT00253526
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer treatment 2 withdrawn NCT00004074
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu treatment 1 completed NCT00331682
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer treatment 2 completed NCT01525082
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors treatment 2 completed NCT01924260
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer treatment 1 completed NCT00088894
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer treatment 3 completed NCT00087191
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer diagnostic Not Available terminated NCT00981162
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride treatment 1 completed NCT01222689
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer treatment 2 completed NCT00577889
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer treatment 2 completed NCT01821612
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer treatment 0 completed NCT00474812
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer treatment 2 completed NCT02153450
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer treatment 0 completed